Kinase-templated abiotic reaction

por Saarbach, J., Lindberg, E., Folliet, S., Georgeon, S., Hantschel, O., Winssinger, N.
Publicado 2017

Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study

por Ludvigsson, J. F., Büsch, K., Olén, O., Askling, J., Smedby, K. E., Ekbom, A., Lindberg, E., Neovius, M.
Publicado 2017

The European Hematology Curriculum: An Electronic Passport Promoting Professional Competence and Mobility

por Almeida, A.M., Ar, C., Hellström-Lindberg, E., Hollegien, W.W.G., Navarro, J.T., Saris, M.T., Wondergem, M.J., Toh, C.H.
Publicado 2018

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

por Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Publicado 2008

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an...

por Fenaux, P, Mufti, GJ, Hellström-Lindberg, E, Santini, V, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, Zimmerman, L, McKenzie, D, Beach, CL, Silverman, LB
Publicado 2008

Correction to: LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide

por Quaife, N. M., Chothani, S., Schulz, J. F., Lindberg, E. L., Vanezis, K., Adami, E., O’Fee, K., Greiner, J., Litviňuková, M., van Heesch, S., Whiffin, N., Hubner, N., Schafer, S., Rackham, O., Cook, S. A., Barton, P. J. R.
Publicado 2022

LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide

por Quaife, N. M., Chothani, S., Schulz, J. F., Lindberg, E. L., Vanezis, K., Adami, E., O’Fee, K., Greiner, J., Litviňuková, M., van Heesch, S., Whiffin, N., Hubner, N., Schafer, S., Rackham, O., Cook, S. A., Barton, P. J. R.
Publicado 2022

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

por Tobiasson, M, Dybedahl, I, Holm, M S, Karimi, M, Brandefors, L, Garelius, H, Grövdal, M, Högh-Dufva, I, Grønbæk, K, Jansson, M, Marcher, C, Nilsson, L, Kittang, A O, Porwit, A, Saft, L, Möllgård, L, Hellström-Lindberg, E
Publicado 2014

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome

por Garelius, H. K. G., Johnston, W. T., Smith, A. G., Park, S., de Swart, L., Fenaux, P., Symeonidis, A., Sanz, G., Čermák, J., Stauder, R., Malcovati, L., Mittelman, M., van de Loosdrecht, A. A., van Marrewijk, C. J., Bowen, D., Crouch, S., de Witte, T. J. M., Hellström‐Lindberg, E.
Publicado 2016